Understanding Early-Onset Bowel Cancer: Biological Differences and Treatment Implications

Biological Differences Emerging Before Age 50

Research suggests that bowel cancer diagnosed before the age of 50 shows distinct characteristics compared to cases diagnosed later in life. A study involving 1,691 Australians with cancer spread only to the liver highlights differences in tumor traits, genetics, and patient survival. Those diagnosed at 50 or younger were more likely to be women and have tumors on the left side of the bowel. Certain genetic mutations were also more common among younger patients.

These biological differences are accompanied by a survival advantage. Younger patients generally lived longer after their cancer spread to the liver compared to older patients. These findings indicate early-onset bowel cancer may differ biologically from cases diagnosed after 50, reinforcing hypotheses previously suspected by researchers.

“We were pleasantly surprised that the findings of the study confirmed our long-held belief that early-onset cancers possess differences in biology and behavior,” Professor Savio George Barreto said.

Genetics’ Role in Treatment Decisions

Genetic mutations like BRAF and KRAS were linked to poorer outcomes for all patients. This emphasizes the importance of genetic testing. Additionally, NRAS mutations emerged as potential guides for treatment strategies. Genetic information is becoming vital in clinical decision-making.

Barreto noted that using BRAF mutations to inform decisions within treatment algorithms is increasing globally. Such information aids in personalizing patient care based on tumor biology.

Treatment Approaches for Younger Patients

Surgical removal of liver tumors followed by drug treatment generally resulted in better outcomes. Differences in treatment approaches were noted between younger and older patients. Upfront curative surgery appeared to offer a survival benefit for younger adults. Yet, certain late-onset patients benefited more from initial chemotherapy.

Researchers stress that while treatment approaches differ, outcomes cannot be directly attributed to the treatments due to real-world clinical data rather than controlled trials.

Supporting Younger Patients Beyond Treatment

Understanding how to support younger survivors, whose needs may vary from older patients, is crucial. Searching for biomarkers that could identify high-risk individuals before cancer develops is a focus area. These markers could enable targeted screening.

“Can we identify epigenetic blood biomarkers of people at risk? This will offer the ability to identify individuals at risk early on with the potential for targeted screening in the future,” Barreto noted.

The study encourages recognizing early-onset bowel cancer as a distinct condition compared to similar diseases in older patients. Different tumor traits, genetic patterns, and improved survival underline the need for personalized treatment approaches tailored to individual patient traits.